Local research. Human connections. WCR Miami Lakes (786) 483-7856
Back to study searchNCT06541535
RecruitingNCT06541535ClinicalTrials.gov record

Fluid Administration in Ketoacidosis (DRINK)

Diabetic Keto-acidosis

THE QUICK READ

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type
Interventional
Phase
Phase 4
Age range
18 years - Not specified
Sex eligible
All sexes
Healthy volunteers
Not accepted
Participants
300 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

Management of severe diabetic ketoacidosis is based on insulin therapy, correction of metabolic disorders and fluid resuscitation. Current recommendations recommend the first-line use of isotonic saline, whose composition is unbalanced, rich in chloride and sodium compared with plasma. Administration of large volumes of isotonic saline is associated with a risk of hyperchloremic metabolic acidosis and acute renal failure. Balanced solutions (e.g. Ringer Lactate) are solutions with a more balanced electrolyte composition close to that of plasma. They could therefore enable diabetic ketoacidosis to be resolved more quickly than isotonic saline, due to a lower risk of hyperchloremic acidosis. Preliminary data suggest a potential benefit of balanced solutions for fluid resuscitation of patients with severe diabetic ketoacidosis in terms of resolution of diabetic ketoacidosis, but no randomized controlled double-blind study to date has compared balanced solution vs. isotonic saline in this context.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

  • Admission to emergency department or direct admission to ICU
  • Diagnosis of severe diabetic ketoacidosis requiring all the following criteria:
  • Blood or capillary glucose \> 11 mmol/L
  • Ketonemia or ketonuria \> 0
  • Venous or arterial pH \< 7.30 or venous or arterial bicarbonate \< 15 mmol/L
  • Volume of fluid administered before inclusion \<1L

Exclusion Criteria:

  • Patients \<18 years
  • Pregnant women
  • Patients under protection
  • Patients with a decision to withdraw life-sustaining therapy
  • Contraindication to isotonic saline or Ringer Lactate
  • Non-affiliation to social security
Understand screening

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment
Random assignment
Masking
Quadruple masked
Isotonic saline

Not reported in this registry record.

Drug: Fluid resuscitation with isotonic saline only

Ringer Lactate

Not reported in this registry record.

Drug: Fluid resuscitation with Ringer Lactate

Fluid resuscitation with isotonic saline only DRUG

Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:

  • During the first hour of treatment:
  • In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.
  • In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.
  • Between 60 minutes and 8 hours of treatment :
  • 1L over 2 hours, repeated once, then 1L over 4 hours
  • Adjust fluid resuscitation according to clinical tolerance
  • After the first 8 hours:
  • 1L over 4h then 1L over 6h
  • Clinical re-evaluation according to standard of care in participating centers
Fluid resuscitation with Ringer Lactate DRUG

Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:

  • During the first hour of treatment:
  • In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.
  • In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.
  • Between 60 minutes and 8 hours of treatment :
  • 1L over 2 hours, repeated once, then 1L over 4 hours
  • Adjust fluid resuscitation according to clinical tolerance
  • After the first 8 hours:
  • 1L over 4h then 1L over 6h
  • Clinical re-evaluation according to standard of care in participating centers
Prepare your questions

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Resolution of diabetic ketoacidosis

Time frame: at 24 hours

Compare fluid resuscitaiton with Ringer Lactate to isotonic saline on the resolution of diabetic ketoacidosis at 24 hours from admission to Intensive Care Unit (ICU) in patients with severe diabetic ketoacidosis.

Resolution of ketoacidosis allowing discharge from ICU, defined as the proportion of patients with the following three criteria at 24 hours from ICU admission :

1. capillary or blood glucose \< 11 mmol/L
2. ketonemia \< 0.6 mmol/l
3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L

Secondary measures

Speed of resolution of metabolic disorders

Time frame: at 48 hours

Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis.

Proportion of patients and number of hours ("Resolution free hours") within 48 hours of ICU admission with the following three criteria:

1. capillary or blood glucose \< 11 mmol/L
2. ketonemia \< 0.6 mmol/l
3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L

Time of resolution of metabolic disorders

Time frame: at 48 hours

Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis.

Time (in hours) from ICU admission to obtain one of the following three criteria:

1. capillary or blood glucose \< 11 mmol/L
2. ketonemia \< 0.6 mmol/l
3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L

Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution

Time frame: through the end of study average 24 months

Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution in patients admitted to ICU for severe diabetic ketoacidosis.

Occurrence of serious metabolic disorders during ICU stay, defined as :

1. Kalemia \< 3 mmol/L
2. Natremia \> 145 mmol/L
3. Chloremia \> 110 mmol/L
4. Phosphoremia \< 0.70 mmol/L
5. Blood glucose \< 3.8 mmol/L (i.e. 0.80 g/L)
6. Persistent ketonemia/ketonuria 24 hours after ICU admission 2. Nature and volume (in liters) of fluid administered before inclusion and during the study period in each group 3. Protocol compliance (expressed as % of volume administered in each group)

Assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications

Time frame: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Occurrence of adverse events during ICU stay, defined as :

1. Neurological disorders (Glasgow score)
2. Acute renal failure (KDIGO classification)
3. Cardiac disorders (supraventricular and ventricular rhythm disorders, acute coronary syndrome) 2. ICU and hospital length of stay 3. ICU mortality and Day-28 mortality

Assess the impact of Ringer lactate compared with isotonic saline on cardiac complications

Time frame: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Occurrence of adverse events during ICU stay, defined as :

  • Cardiac disorders (supraventricular and ventricular rhythm disorders, acute coronary syndrome)
  • ICU and hospital length of stay
  • ICU mortality and Day-28 mortality
Assess the impact of Ringer lactate compared with isotonic saline on renal complications

Time frame: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on renal, complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Measure acute renal failure with KDIGO classification.

The Kidney Disease: Improving Global Outcomes (KDIGO) classification system stratifies acute kidney injury (AKI) into levels of severity, determined by changes in serum creatinine (SCr) / estimated creatinine clearance (eCCl), as well as changes in urine output. The strata of severity of AKI can be reached by meeting the criteria for changes in SCr / eCCl or changes in urine output. There are three levels of severity, with level 1 being the least severe and level 3 the most severe.

No cut-off for the study

Assess the impact of Ringer lactate compared with isotonic saline on neurological complications

Time frame: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on neurological complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Measure Neurological disorders with Glasgow score. The Glasgow Coma Scale (GCS) is used to objectively describe the extent of impaired consciousness in all types of patients. The scale rates patients on three aspects of reactivity: eye opening, motor responses and verbal responses. It ranges from 3 (coma) to 15 (no disturbance of consciousness). No cut-off for the study.

No results are flagged as posted.

Review the complete result tables and limitations in the official record.

Open official results ↗

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

CHU NICENice, FranceRecruiting

Study team and timeline

Lead sponsor
Centre Hospitalier Universitaire de Nice
Study start
Nov 26, 2025 Actual
Primary completion
2027-12 Estimated
Study completion
2028-07 Estimated
First posted
Aug 7, 2024 Actual
Last updated
Nov 10, 2026 Actual

Official study contacts

Mathieu JOZWIAK, MD PhDCONTACTjozwiak.m@chu-nice.fr+33492035510
Official study title

Comparison of Saline and Ringer Lactate in Patients With Severe Diabetic Ketoacidosis (DRINK) : a Double-blind Randomized Controlled Trial

A HUMAN NEXT STEP

Ask Wellness Clinical Research

Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.

Please do not include medical records, diagnoses, medications, insurance numbers or other sensitive details. This form is for general questions, not urgent care.

Sending a question does not enroll you in a trial.

Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.

Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026